Announced Thu, 2 Jul · 18:36 IST
Brooks Labs incorporates wholly owned subsidiary Abridge Speciality
Strategic Transactions View source PDF
BROOKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.2%1-day move
₹75.91
prior close
₹78.65
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
———+0.4+1.2-3.8-6.6-6.5-7.8-7.7-15.7———
Up moveDown movePending
AI summary
Brooks Laboratories has incorporated a wholly owned subsidiary named Abridge Speciality Limited on July 2, 2026. The new entity will operate in manufacturing and marketing of pharmaceuticals. It has an authorized share capital of Rs. 1 Lakh and is yet to commence operations. Brooks Labs holds 100% of the new company and says the move supports its strategic business expansion.
Likely market impact
Minor corporate move with negligible near term financial impact; positions the company for future growth in pharma segment.